(See also Approach to Parasitic Infections.)
Strongyloidiasis is one of the major soil-transmitted parasitic diseases. An estimated 30 to100 million people are infected worldwide. Strongyloidiasis is endemic throughout the tropics and subtropics, including rural areas of the southern United States, at sites where bare skin is exposed to infective larvae in soil contaminated by human feces. S. stercoralis has the unique ability to develop to adulthood in soil as well as the human intestine. Furthermore, unlike other soil-transmitted roundworms, S. stercoralis is capable of autoinfection, which can result in chronic disease lasting decades, or cause overwhelming hyperinfection in people taking corticosteroids or other immunosuppressive drugs or who have impaired TH2 type cell-mediated immunity, particularly those infected with the human T-lymphotropic virus 1 (HTLV-1).
During hyperinfection, large numbers of larvae gain access to the bloodstream, lungs, central nervous system, and other organs. Polymicrobial bacteremia and meningitis can occur due to disruption of intestinal mucosa and the presence of bacteria on the surface of invading larvae.
Serious S. stercoralis infections have occurred in recipients of solid organ transplants, both in those with pre-existant subclinical infection and in those who have received organs from asymptomatic but infected donors (1).
Strongyloides fülleborni, which infects chimpanzees and baboons, can cause limited infections in humans.
1. Abanyie FA, Gray EB, Delli Carpini KW, et al: Donor-derived Strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009–2013. Am J Transplant 15 (5):1369–1375, 2015. doi: 10.1111/ajt.13137
Strongyloides adult worms live in the mucosa and submucosa of the duodenum and jejunum. Released eggs hatch in the bowel lumen, liberating rhabditiform larvae. Most of the larvae are excreted in the stool. After a few days in soil, they develop into infectious filariform larvae. Like hookworms, Strongyloides larvae penetrate human skin, migrate via the bloodstream to the lungs, break through pulmonary capillaries, ascend the respiratory tract, are swallowed, and reach the intestine, where they mature in about 2 weeks. In the soil, larvae that do not contact humans may develop into free-living adult worms that can reproduce for several generations before their larvae reenter a human host.
Some rhabditiform larvae convert within the intestine to infectious filariform larvae that immediately reenter the bowel wall, short-circuiting the life cycle (internal autoinfection). Sometimes filariform larvae are passed in stool; if the stool contaminates the skin (eg, of the buttocks or thighs), larvae can reenter through the skin (external autoinfection).
Autoinfection explains why strongyloidiasis can persist for many decades and helps account for the extremely high worm burden in the hyperinfection syndrome and disseminated strongyloidiasis.
Hyperinfection syndrome may result from a newly acquired Strongyloides infection or from activation of a previously asymptomatic one. In either case, it can result in disseminated disease in which organs that are not usually part of the parasite’s normal life cycle (eg, central nervous system [CNS], skin, liver, heart) are affected. Hyperinfection typically occurs in people who have impaired TH2 type cell-mediated immunity including those taking corticosteroids, receiving immunosuppressive therapy for solid organ or hematopoietic stem cell transplants, or infected with the human T-lymphotropic virus 1 (HTLV-1). Hyperinfection has also been associated with alcoholism and malnutrition. However, hyperinfection and disseminated strongyloidiasis are less common than might be predicted among patients with HIV/AIDS, even those living in areas where Strongyloides is highly endemic.
Patients with undiagnosed strongyloidiasis may progress to hyperinfection or disseminated disease if corticosteroid therapy is initiated, including patients with COVID-19 receiving dexamethasone or other corticosteroids. A test-and-treat strategy has been proposed for people who may have been exposed (eg, in endemic regions) to S. stercoralis (1).
1. Stauffer WM, Alpern JD, Walker PF: COVID-19 and Dexamethasone: A potential strategy to avoid steroid-related Strongyloides hyperinfection [published online ahead of print, 2020 Jul 30]. JAMA. 10.1001/jama.2020.13170. doi:10.1001/jama.2020.13170
Acute and chronic strongyloidiasis can be asymptomatic.
With acute strongyloidiasis, the initial manifestation can be a pruritic, erythematous rash at the site where larvae entered the skin. A cough may develop as larvae migrate through the lungs and trachea. Larvae and adult worms in the gastrointestinal tract can cause abdominal pain, diarrhea, and anorexia.
Chronic strongyloidiasis can persist for years due to autoinfection. It may be asymptomatic or characterized by gastrointestinal, pulmonary, and/or cutaneous symptoms. Gastrointestinal complaints include abdominal pain and intermittent diarrhea and constipation. Tests for occult blood in stool may be positive, and on rare occasion, frank gastrointestinal hemorrhage can occur. The symptoms can mimic the symptoms of ulcerative colitis, those of other causes of chronic malabsorption, or duodenal obstruction.
Larva currens (creeping infection) is a form of cutaneous larva migrans specific to Strongyloides infection; it results from autoinfection. The eruption usually begins in the perianal region and is accompanied by intense pruritus. Typically, larva currens is a linear or serpiginous, rapidly migrating (up to 10 cm/hour), erythematous, urticarial skin lesion. Nonspecific maculopapular or urticarial eruptions may also occur.
Pulmonary symptoms are uncommon, although heavy infections may cause Löffler syndrome, with cough, wheezing, and eosinophilia as auto-infecting larvae pass through the lungs. The symptoms can suggest allergic asthma or chronic obstructive pulmonary disease (COPD).
Gastrointestinal and pulmonary symptoms are often prominent. Bacteremia may develop when the larvae invade the bowel disrupting the mucosa and carrying bacteria on their surface. Ileus, obstruction, massive gastrointestinal bleeding, severe malabsorption, and peritonitis may occur. Pulmonary symptoms include dyspnea, hemoptysis, and respiratory failure. Infiltrates may be seen on chest x-ray or CT scan.
Other symptoms depend on the organs involved. Central nervous system (CNS) involvement includes parasitic meningitis, brain abscess, and diffuse invasion of the brain. Secondary gram-negative meningitis and bacteremia, which occurs with high frequency, probably reflect disruption of bowel mucosa, carriage of bacteria on migrating larvae, or both. Liver infection may result in cholestatic and granulomatous hepatitis.
Hyperinfection and disseminated strongyloidiasis are often fatal in immunocompromised patients, even with treatment.
Microscopic examination of a single stool sample detects larvae in about 25% of uncomplicated Strongyloides infections. Repeated examination of concentrated stool samples raises the sensitivity; a minimum of 3 and up to 7 stool samples is recommended. Specialized methods of stool examination increase the sensitivity. They include nutrient agar plate culture, the Baermann funnel technique, and the Harada-Mori filter paper technique.
Endoscopic small bowel aspiration or biopsy of suspicious duodenal or jejunal lesions may be positive in low-level infections.
In hyperinfection syndrome and disseminated strongyloidiasis, filariform larvae may be found in stool, duodenal contents, sputum, and bronchial washings and, uncommonly, in cerebrospinal fluid (CSF), urine, or pleural or ascitic fluid. They may also be seen in biopsies of lung tissue or tissue of other organs. Chest x-rays may show diffuse interstitial infiltrates, consolidation, or abscess.
Several immunodiagnostic tests are available to identify anti-strongyloides antibodies in serum. Enzyme immunoassay (EIA) is recommended because of its greater sensitivity (> 90%). Serum IgG antibodies can usually be detected even in immunocompromised patients with disseminated strongyloidiasis, but the absence of detectable antibodies does not exclude infection. Cross-reactions in patients with filariasis or other nematode infections may result in false-positive tests. Antibody test results cannot be used to differentiate current from past infection. A positive test warrants continuing efforts to establish a parasitologic diagnosis.
Serologic monitoring may be useful in follow-up because antibody levels decrease within 6 months of successful chemotherapy.
Molecular tests for the diagnosis of S. stercoralis, including polymerase chain reaction (PCR)-based methods, are available at some reference laboratories. Sensitivity and specificity of molecular tests vary, and they have not yet replaced microscopy and serology for diagnosis.
Eosinophilia is often present but can be suppressed by drugs such as corticosteroids or cytotoxic chemotherapeutic drugs.
People who were possibly exposed to Strongyloides should be screened using stool examinations and/or serologic testing. Candidates for screening include people with a history of travel to or residence in endemic areas (recently or even in the distant past) and any of the following:
Symptoms that suggest strongyloidiasis
Infected with HTLV-1
Impending organ transplant (recipient or donor)
Impending treatment with corticosteroids
Patients with HIV/AIDS do not appear to be at a disproportionally high risk of hyperinfection or disseminated strongyloidiasis and are not candidates for screening in the absence of other risk factors.
All patients with strongyloidiasis should be treated. The cure rate is higher with ivermectin than albendazole (1).
Ivermectin 200 mcg/kg orally once a day for 2 days is used for uncomplicated infection and is generally well-tolerated. Before treatment with ivermectin, patients should be assessed for coinfection with Loa loa if they have lived in or traveled to areas of central Africa where Loa loa is endemic because ivermectin can cause severe reactions in patients with loiasis and high microfilarial levels. Albendazole 400 mg orally twice a day for 7 days is an alternative for treatment of strongyloidiasis.
Immunocompromised patients require prolonged therapy until sputum and/or stool are negative for 2 weeks. Sometimes repeated courses of treatment are needed. In severely ill patients who are unable to take oral drugs, rectal preparations of ivermectin or the veterinary subcutaneous formulation of ivermectin has been used.
Hyperinfection syndrome and disseminated strongyloidiasis in patients with strongyloidiasis are life-threatening medical emergencies. Ivermectin 200 mcg/kg orally once a day is continued until sputum and stool examinations for rhabditiform and filariform larvae are negative for 2 weeks. Broad-spectrum antibiotics are used to treat concurrent polymicrobial bacterial infections associated with larval invasion from the bowel.
After treatment of strongyloidiasis, cure should be documented by repeated stool examinations 2 to 4 weeks later. If the stool remains positive, retreatment is indicated.
1. Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al: Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev 18 (1):CD007745, 2016. doi: 10.1002/14651858.CD007745.pub3
Prevention of primary Strongyloides infections is the same as for hookworms. It involves
Strongyloides larvae penetrate human skin when people walk barefoot or sit on infested soil.
Larvae travel through the bloodstream to the lungs, penetrate the alveoli, ascend the respiratory tract, are swallowed, and then mature in the intestines; adult worms produce ova that hatch in the intestines, releasing larvae; they can develop into infective filariform larvae, which may cause external or internal autoinfection, perpetuating the cycle.
Patients who are coinfected with HTLV-1, who are taking corticosteroids, or who have impaired cell-mediated immunity for other reasons may develop potentially fatal hyperinfection syndrome—disseminated disease involving the lungs, intestines, skin, and other organs that are not part of the parasite’s normal life cycle (eg, central nervous system [CNS], liver, heart).
Symptoms include rash, pulmonary symptoms (including cough and wheezing), and abdominal pain with diarrhea.
Diagnose by microscopic examination of multiple stool samples, the agar plate method, or duodenal aspirate; larvae may be identified in sputum in patients with hyperinfection.
Treat uncomplicated infections with ivermectin for 2 days; albendazole for 7 days is an alternative.
Hyperinfection syndrome and disseminated strongyloidiasis require prolonged ivermectin treatment.
For all Strongyloides infections, document cure by repeated stool examinations.
Drugs Mentioned In This Article
|Drug Name||Select Trade|